# TCGX Acquisition (TCGX) — News

TCGX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tcgx/news

## Recent headlines

- [TCGX Acquisition II to list 10M shares at $10.00](https://www.ainvest.com/news/tcgx-acquisition-ii-list-10m-shares-10-00-2610) — AInvest Wire, Oct 15, 2026
  TCGX Acquisition Corp. has announced the pricing of its initial public offering (IPO), raising $75 million by listing 7.5 million shares at $10.00 per share. The company, a blank check entity formed to pursue a merger or acquisition with an operating business, completed its IPO on the Nasdaq . The…
- [TCGX Acquisition II prices $100M IPO on Nasdaq](https://www.ainvest.com/news/tcgx-acquisition-ii-prices-100m-ipo-nasdaq-2610) — AInvest Wire, Oct 15, 2026
  TCGX Acquisition II has priced its initial public offering at $100 million on the Nasdaq, marking a significant step in its corporate development. The offering, which went public on October 15, 2026, reflects continued investor interest in the company’s strategic positioning and growth potential.…
- [Tavexia Lifecare - Board approves acquisition of 60% controlling stake in Meyonex Pharmaceuticals](https://www.ainvest.com/news/tavexia-lifecare-board-approves-acquisition-60-controlling-stake-meyonex-pharmaceuticals-2610) — AInvest Wire, Oct 12, 2026
  Tavexia Lifecare Limited (TAVX) has announced that its board of directors has approved the acquisition of a 60% controlling stake in Meyonex Pharmaceuticals. The move is expected to strengthen Tavexia’s position in the pharmaceutical sector by expanding its product portfolio and enhancing its…
- [TCGX: Closes oversubscribed $600 mln Asia life sciences fund I focused on Asian biotechnology companies](https://www.ainvest.com/news/tcgx-closes-oversubscribed-600-mln-asia-life-sciences-fund-focused-asian-biotechnology-companies-2610) — AInvest Wire, Oct 7, 2026
  TCGX, a healthcare investment firm focused on advancing disruptive medicines, has announced the successful closure of its oversubscribed $600 million Asia Life Sciences Fund I, dedicated to investing in biotechnology companies across Asia. The fund, which exceeded its initial target, reflects…
- [TCGX Acquisition II files for $100M SPAC IPO](https://www.ainvest.com/news/tcgx-acquisition-ii-files-100m-spac-ipo-2609) — AInvest Wire, Sep 25, 2026
  TCGX Acquisition II, a special purpose acquisition company (SPAC), has filed for a $100 million initial public offering (IPO), according to recent filings. The offering is intended to raise capital for a potential merger with a private company in the healthcare or life sciences sectors. SPACs have…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).